CCR5 antagonists for the treatment of HIV infection and AIDS

Advances in Antiviral Drug Design

Volumn 5, Issue , 2007, Pages 185-212

  Perros, Manos ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 48349104816     PISSN: 10758593     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1075-8593(06)05005-2     Document Type: Review

References (114)

1. S. Abel, E. Van der Ryst, G.J. Muihead, A. Rosario, A. Edgington, G. Weissgerber, Pharmacokinetics of single and multiple oral doses of UK-427,857-A novel CCR5 antagonist in healthy volunteers, in: 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003
2. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., and Berger E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
3. Armour D.R., de Groot M.J., Price D.A., Stammen B.L., Wood A., Perros M., and Burt C. The discovery of tropane-derived CCR5 receptor antagonists. Chem. Biol. Drug. Des. 67 (2006) 305-308
4. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96 (1999) 5698-5703
5. Baba M., Takashima K., Miyake H., Kanzaki N., Teshima K., Wang X., Shiraishi M., and Iizawa Y. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother. 49 (2005) 4584-4591
6. Blair W.S., Isaacson J., Li X., Cao J., Peng Q., Kong G.F., and Patick A.K. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antiviral. Res. 65 (2005) 107-116
7. Bradley J., Gill J., Bertelli F., Letafat S., Corbau R., Hayter P., Harrison P., Tee A., Keighley W., Perros M., Ciaramella G., Sewing A., and Williams C. Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry. J. Biomol. Screen 9 (2004) 516-524
8. Brumme Z.L., Goodrich J., Mayer H.B., Brumme C.J., Henrick B.M., Wynhoven B., Asselin J.J., Cheung P.K., Hogg R.S., Montaner J.S., and Harrigan P.R. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J. Infect. Dis. 192 (2005) 466-474
9. Bursill C.A., Channon K.M., and Greaves D.R. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr. Opin. Lipidol. 15 (2004) 145-149
10. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug. Discov. 2 (2003) 624-634
11. Castonguay L.A., Weng Y., Adolfsen W., Di Salvo J., Kilburn R., Caldwell C.G., Daugherty B.L., Finke P.E., Hale J.J., Lynch C.L., Mills S.G., MacCoss M., Springer M.S., and DeMartino J.A. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 42 (2003) 1544-1550
12. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
13. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., Wu L., Mackay C.R., LaRosa G., Newman W., Gerard N., Gerard C., and Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85 (1996) 1135-1148
14. Coakley E., Petropoulos C.J., and Whitcomb J.M. Assessing chemokine co-receptor usage in HIV. Curr. Opin. Infect. Dis. 18 (2005) 9-15
15. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., and Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8 + T cells. Science 270 (1995) 1811-1815
16. Combadiere C., Ahuja S.K., Tiffany H.L., and Murphy P.M. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J. Leukoc. Biol. 60 (1996) 147-152
17. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., Goedert J.J., Buchbinder S.P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R., and O'Brien S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273 (1996) 1856-1862
18. J.A. DeMartino, CCR5 Blockade modulates alloimmunity in primates, in: 231st Annual ACS Meeting, Atlanta, GA, 2006
19. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., and Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (1996) 661-666
20. S. Dobbs, M. Perros, G.A. Rickett, An assay method for determining whether an agent is capable of modulating the interaction of CCR5 with gp120, 2001
21. Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., Parmentier M., Collman R.G., and Doms R.W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 (1996) 1149-1158
22. Dorn C.P., Finke P.E., Oates B., Budhu R.J., Mills S.G., MacCoss M., Malkowitz L., Springer M.S., Daugherty B.L., Gould S.L., DeMartino J.A., Siciliano S.J., Carella A., Carver G., Holmes K., Danzeisen R., Hazuda D., Kessler J., Lineberger J., Miller M., Schleif W.A., and Emini E.A. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 11 (2001) 259-264
23. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., Webster R., Armour D., Price D., Stammen B., Wood A., and Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49 (2005) 4721-4732
24. P.K. Dorr, K. Todd, R. Irvine, N. Robas, A. Thomas, M. Fidock, H. Sultan, J. Mills, F. Perrucio, K. Burt, G. Rickett, H. Perkins, P. Griffin, M. Macartney, D. Hamilton, M. Westby, M. Perros, Site-directed mutagenesis studies of CCR5 reveal differences in the interactions between the receptor and various CCR5 antagonists, in: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 2005
25. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., Cayanan C., Maddon P.J., Koup R.A., Moore J.P., and Paxton W.A. HIV-1 entry into CD4 + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996) 667-673
26. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., Lin S.W., Ying W., Smith S.O., Sakmar T.P., and Moore J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. USA 97 (2000) 5639-5644
27. Eri R., Jonsson J.R., Pandeya N., Purdie D.M., Clouston A.D., Martin N., Duffy D., Powell E.E., Fawcett J., Florin T.H., and Radford-Smith G.L. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes. Immun. 5 (2004) 444-450
28. Este J.A. Sch-351125 and Sch-350634. Schering-Plough. Curr. Opin. Investig. Drugs. 3 (2002) 379-383
29. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., Saag M.S., Goebel F.D., Rockstroh J.K., Dezube B.J., Jenkins T.M., Medhurst C., Sullivan J.F., Ridgway C., Abel S., James I.T., Youle M., and van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11 (2005) 1170-1172
30. Feng Y., Broder C.C., Kennedy P.E., and Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 (1996) 872-877
31. Fildes J.E., Walker A.H., Howlett R., Bittar M.N., Hutchinson I.V., Leonard C.T., and Yonan N. Donor CCR5 Delta32 polymorphism and outcome following cardiac transplantation. Transplant. Proc. 37 (2005) 2247-2249
32. Goulding C., McManus R., Murphy A., MacDonald G., Barrett S., Crowe J., Hegarty J., McKiernan S., and Kelleher D. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 54 (2005) 1157-1161
33. W. Greaves, R. Landovitz, G. Fatkenheuer, C. Hoffmann, F. Antunes, J. Angel, N. Boparai, D. Knepp, A. Keung, L. Dunkle, Late virologic breakthrough in treatment-naive patients on a regimen of combivir + vicriviroc, in: 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006
34. Greenberg M.L., and Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54 (2004) 333-340
35. G. Hanna, J. Lalezari, J. Hellinger, D. Wohl, T. Masterson, W. Fiske, J. Kadow, P. Lin, M. Giordano, R. Colonno, D.S.F. Grasela, Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects, in: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, 2004. Abstract 141
36. Henckaerts L., Fevery J., Van Steenbergen W., Verslype C., Yap P., Nevens F., Roskams T., Libbrecht L., Rutgeerts P., and Vermeire S. CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis. Inflamm. Bowel. Dis. 12 (2006) 272-277
37. Hendrix C.W., Collier A.C., Lederman M.M., Schols D., Pollard R.B., Brown S., Jackson J.B., Coombs R.W., Glesby M.J., Flexner C.W., Bridger G.J., Badel K., MacFarland R.T., Henson G.W., and Calandra G. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 37 (2004) 1253-1262
38. Holland A.U., Munk C., Lucero G.R., Nguyen L.D., and Landau N.R. Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion. Virology 319 (2004) 343-352
39. Huang Y., Paxton W.A., Wolinsky S.M., Neumann A.U., Zhang L., He T., Kang S., Ceradini D., Jin Z., Yazdanbakhsh K., Kunstman K., Erickson D., Dragon E., Landau N.R., Phair J., Ho D.D., and Koup R.A. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2 (1996) 1240-1243
40. Imamura S., Ichikawa T., Nishikawa Y., Kanzaki N., Takashima K., Niwa S., Iizawa Y., Baba M., and Sugihara Y. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity. J. Med. Chem. 49 (2006) 2784-2793
41. Jacobson J.M., Lowy I., Fletcher C.V., O'Neill T.J., Tran D.N., Ketas T.J., Trkola A., Klotman M.E., Maddon P.J., Olson W.C., and Israel R.J. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182 (2000) 326-329
42. Jenkinson S., McCoy D.C., Kerner S.A., Ferris R.G., Lawrence W.K., Clay W.C., Condreay J.P., and Smith C.D. Development of a novel high-throughput surrogate assay to measure HIV envelope/CCR5/CD4-mediated viral/cell fusion using BacMam baculovirus technology. J. Biomol. Screen 8 (2003) 463-470
43. Ji C., Zhang J., Cammack N., and Sankuratri S. Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression. J. Biomol. Screen 11 (2006) 65-74
44. Karlsson I., Antonsson L., Shi Y., Karlsson A., Albert J., Leitner T., Olde B., Owman C., and Fenyo E.M. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 17 (2003) 2561-2569
45. Koning F.A., Kwa D., Boeser-Nunnink B., Dekker J., Vingerhoed J., Hiemstra H., and Schuitemaker H. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 188 (2003) 864-872
46. Kuritzkes D.R., Jacobson J., Powderly W.G., Godofsky E., DeJesus E., Haas F., Reimann K.A., Larson J.L., Yarbough P.O., Curt V., and Shanahan Jr. W.R. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189 (2004) 286-291
47. Lalezari J., Thompson M., Kumar P., Piliero P., Davey R., Patterson K., Shachoy-Clark A., Adkison K., Demarest J., Lou Y., Berrey M., and Piscitelli S. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 19 (2005) 1443-1448
48. Lee B., Sharron M., Blanpain C., Doranz B.J., Vakili J., Setoh P., Berg E., Liu G., Guy H.R., Durell S.R., Parmentier M., Chang C.N., Price K., Tsang M., and Doms R.W. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274 (1999) 9617-9626
49. Lin P.F., Blair W., Wang T., Spicer T., Guo Q., Zhou N., Gong Y.F., Wang H.G., Rose R., Yamanaka G., Robinson B., Li C.B., Fridell R., Deminie C., Demers G., Yang Z., Zadjura L., Meanwell N., and Colonno R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA 100 (2003) 11013-11018
50. P.F. Lin, H.T. Ho, Y.F. Gong, I. Dicker, N. Zhou, L. Fan, B. McAuliffe, B. Kimmel, B. Nowicka-Sans, T. Wang, J. Kadow, G. Yamanaka, Z. Lin, N. Meanwell, R. Colonno, Characterization of a small molecule HIV-1 attachment inhibitor BMS-488043: virology, resistance and mechanism of action, in: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004
51. Lipinski C.A. Chris Lipinski discusses life and chemistry after the Rule of Five. Drug. Discov. Today 8 (2003) 12-16
52. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellmann N.S., and Richman D.D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347 (2002) 385-394
53. Litwin V., Nagashima K.A., Ryder A.M., Chang C.H., Carver J.M., Olson W.C., Alizon M., Hasel K.W., Maddon P.J., and Allaway G.P. Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer. J. Virol. 70 (1996) 6437-6441
54. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., and Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
55. Lusso P. Chemokines and viruses: the dearest enemies. Virology 273 (2000) 228-240
56. Madani N., Perdigoto A.L., Srinivasan K., Cox J.M., Chruma J.J., LaLonde J., Head M., Smith III A.B., and Sodroski J.G. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J. Virol. 78 (2004) 3742-3752
57. Maddon P.J., Dalgleish A.G., McDougal J.S., Clapham P.R., Weiss R.A., and Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47 (1986) 333-348
58. Maeda K., Das D., Ogata-Aoki H., Nakata H., Miyakawa T., Tojo Y., Norman R., Takaoka Y., Ding J., Arnold G.F., Arnold E., and Mitsuya H. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281 (2006) 12688-12698
59. Maeda K., Nakata H., Koh Y., Miyakawa T., Ogata H., Takaoka Y., Shibayama S., Sagawa K., Fukushima D., Moravek J., Koyanagi Y., and Mitsuya H. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78 (2004) 8654-8662
60. Maeda K., Yoshimura K., Shibayama S., Habashita H., Tada H., Sagawa K., Miyakawa T., Aoki M., Fukushima D., and Mitsuya H. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. 276 (2001) 35194-35200
61. Maeda Y., Foda M., Matsushita S., and Harada S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J. Virol. 74 (2000) 1787-1793
62. McMahon J.B., Beutler J.A., O'Keefe B.R., Goodrum C.B., Myers M.A., and Boyd M.R. Development of a cyanovirin-N-HIV-1 gp120 binding assay for high throughput screening of natural product extracts by time-resolved fluorescence. J. Biomol. Screen 5 (2000) 169-176
63. J. Mori, M. Westby, M. Perros, The effect of Maraviroc (UK-427,857) in combination with HIV-1 nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors and Entry inhibitors against acute HIV-1 infection in vitro, in: 10th European AIDS conference, Dublin, Ireland, 2005
64. Mosier D.E., Picchio G.R., Gulizia R.J., Sabbe R., Poignard P., Picard L., Offord R.E., Thompson D.A., and Wilken J. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73 (1999) 3544-3550
65. Moyle G.J., Wildfire A., Mandalia S., Mayer H., Goodrich J., Whitcomb J., and Gazzard B.G. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. 191 (2005) 866-872
66. Mueller A., and Strange P.G. The chemokine receptor, CCR5. Int. J. Biochem. Cell. Biol. 36 (2004) 35-38
67. Navenot J.M., Wang Z.X., Trent J.O., Murray J.L., Hu Q.X., DeLeeuw L., Moore P.S., Chang Y., and Peiper S.C. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding. J. Mol. Biol. 313 (2001) 1181-1193
68. W.C. Olson, H. Doshan, C. Zhan, J. Mezzatasta, A. Assumma, R. Czarnecky, J. Stavola, P. Maddon, A. Kremer, R. Israel, Prolonged Coating of CCR5 Lymphocytes by PRO 140, a Humanized CCR5 Monoclonal Antibody for HIV-1 Therapy, in: 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006
69. Olson W.C., Rabut G.E., Nagashima K.A., Tran D.N., Anselma D.J., Monard S.P., Segal J.P., Thompson D.A., Kajumo F., Guo Y., Moore J.P., Maddon P.J., and Dragic T. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73 (1999) 4145-4155
70. M. Perros, Plenary lecture, in: 18th International Conference on Antiviral Research, Barcelona, Spain, 2005
71. Perry M., Stansfeld P.J., Leaney J., Wood C., de Groot M.J., Leishman D., Sutcliffe M.J., and Mitcheson J.S. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol. Pharmacol. 69 (2006) 509-519
72. Pierson T.C., Doms R.W., and Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev. Med. Virol. 14 (2004) 255-270
73. Pokorny V., McQueen F., Yeoman S., Merriman M., Merriman A., Harrison A., Highton J., and McLean L. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann. Rheum. Dis. 64 (2005) 487-490
74. Prahalad S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun. 7 (2006) 264-268
75. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., and Bozzette S.A. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
76. G. Rickett, S. Dobbs, P. Griffin, P. Dorr, C. Hitchcock, M. Perros, Development of a high throughput time resolved fluorescence immunoassay to support discovery of HIV-1 cell entry Inhibitors, in: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003
77. D. Russell, A. Bakhtyari, R.P. Jazrawi, L. Whitlock, C. Ridgway, M. McHale, S. Abel, Multiple dose study to investigate the safety of UK-427,857 (100mg or 300 mg) BID for 28 days in healthy males and females, in: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2003
78. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., and Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (1996) 722-725
79. Schramm B., Penn M.L., Speck R.F., Chan S.Y., De Clercq E., Schols D., Connor R.I., and Goldsmith M.A. Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease. J. Virol. 74 (2000) 184-192
80. Schuitemaker H., Kootstra N.A., de Goede R.E., de Wolf F., Miedema F., and Tersmette M. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J. Virol. 65 (1991) 356-363
81. Seibert C., Ying W., Gavrilov S., Tsamis F., Kuhmann S.E., Palani A., Tagat J.R., Clader J.W., McCombie S.W., Baroudy B.M., Smith S.O., Dragic T., Moore J.P., and Sakmar T.P. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349 1 (2006) 41-54
82. Shafti-Keramat S., Handisurya A., Kriehuber E., Meneguzzi G., Slupetzky K., and Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77 (2003) 13125-13135
83. Shankarappa R., Margolick J.B., Gange S.J., Rodrigo A.G., Upchurch D., Farzadegan H., Gupta P., Rinaldo C.R., Learn G.H., He X., Huang X.L., and Mullins J.I. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73 (1999) 10489-10502
84. Shen D.M., Shu M., Mills S.G., Chapman K.T., Malkowitz L., Springer M.S., Gould S.L., DeMartino J.A., Siciliano S.J., Kwei G.Y., Carella A., Carver G., Holmes K., Schleif W.A., Danzeisen R., Hazuda D., Kessler J., Lineberger J., Miller M.D., and Emini E.A. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains. Bioorg. Med. Chem. Lett. 14 (2004) 935-939
85. Shen D.M., Shu M., Willoughby C.A., Shah S., Lynch C.L., Hale J.J., Mills S.G., Chapman K.T., Malkowitz L., Springer M.S., Gould S.L., DeMartino J.A., Siciliano S.J., Lyons K., Pivnichny J.V., Kwei G.Y., Carella A., Carver G., Holmes K., Schleif W.A., Danzeisen R., Hazuda D., Kessler J., Lineberger J., Miller M.D., and Emini E.A. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds. Bioorg. Med. Chem. Lett. 14 (2004) 941-945
86. Shet A., Berry L., Mohri H., Mehandru S., Chung C., Kim A., Jean-Pierre P., Hogan C., Simon V., Boden D., and Markowitz M. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J. Acquir. Immune Defic. Syndr. 41 (2006) 439-446
87. Shiraishi M., Aramaki Y., Seto M., Imoto H., Nishikawa Y., Kanzaki N., Okamoto M., Sawada H., Nishimura O., Baba M., and Fujino M. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J. Med. Chem. 43 (2000) 2049-2063
88. Shu M., Loebach J.L., Parker K.A., Mills S.G., Chapman K.T., Shen D.M., Malkowitz L., Springer M.S., Gould S.L., DeMartino J.A., Siciliano S.J., Salvo J.D., Lyons K., Pivnichny J.V., Kwei G.Y., Carella A., Carver G., Holmes K., Schleif W.A., Danzeisen R., Hazuda D., Kessler J., Lineberger J., Miller M.D., and Emini E.A. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment. Bioorg. Med. Chem. Lett. 14 (2004) 947-952
89. Siciliano S.J., Kuhmann S.E., Weng Y., Madani N., Springer M.S., Lineberger J.E., Danzeisen R., Miller M.D., Kavanaugh M.P., DeMartino J.A., and Kabat D. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. J. Biol. Chem. 274 (1999) 1905-1913
90. Skehel J.J., and Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69 (2000) 531-569
91. Strizki J.M., Tremblay C., Xu S., Wojcik L., Wagner N., Gonsiorek W., Hipkin R.W., Chou C.C., Pugliese-Sivo C., Xiao Y., Tagat J.R., Cox K., Priestley T., Sorota S., Huang W., Hirsch M., Reyes G.R., and Baroudy B.M. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49 (2005) 4911-4919
92. Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., Endres M., Palani A., Shapiro S., Clader J.W., Greenlee W.J., Tagat J.R., McCombie S., Cox K., Fawzi A.B., Chou C.C., Pugliese-Sivo C., Davies L., Moreno M.E., Ho D.D., Trkola A., Stoddart C.A., Moore J.P., Reyes G.R., and Baroudy B.M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98 (2001) 12718-12723
93. Takashima K., Miyake H., Kanzaki N., Tagawa Y., Wang X., Sugihara Y., Iizawa Y., and Baba M. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob. Agents Chemother. 49 (2005) 3474-3482
94. Thelen M. Dancing to the tune of chemokines. Nat. Immunol. 2 (2001) 129-134
95. Tomkowicz B., Lee C., Ravyn V., Cheung R., Ptasznik A., and Collman R. The Src kinase Lyn is required for CCR5 signaling in response to MIP-1{beta} and R5 HIV-1 gp120 in human macrophages. Blood 108 4 (2006) 1145-1150
96. Tremblay C.L., Giguel F., Chou T.C., Dong H., Takashima K., and Hirsch M.S. TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro. Antivir. Ther. 10 (2005) 967-968
97. Tremblay C.L., Giguel F., Guan Y., Chou T.C., Takashima K., and Hirsch M.S. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. Antimicrob. Agents Chemother. 49 (2005) 3483-3485
98. Tremblay C.L., Giguel F., Kollmann C., Guan Y., Chou T.C., Baroudy B.M., and Hirsch M.S. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46 (2002) 1336-1339
99. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng-Mayer C., Robinson J., Maddon P.J., and Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384 (1996) 184-187
100. Trkola A., Ketas T.J., Nagashima K.A., Zhao L., Cilliers T., Morris L., Moore J.P., Maddon P.J., and Olson W.C. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75 (2001) 579-588
101. Trkola A., Kuhmann S.E., Strizki J.M., Maxwell E., Ketas T., Morgan T., Pugach P., Xu S., Wojcik L., Tagat J., Palani A., Shapiro S., Clader J.W., McCombie S., Reyes G.R., Baroudy B.M., and Moore J.P. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA 99 (2002) 395-400
102. Tsamis F., Gavrilov S., Kajumo F., Seibert C., Kuhmann S., Ketas T., Trkola A., Palani A., Clader J.W., Tagat J.R., McCombie S., Baroudy B., Moore J.P., Sakmar T.P., and Dragic T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77 (2003) 5201-5208
103. van Wanrooij E.J., Happe H., Hauer A.D., de Vos P., Imanishi T., Fujiwara H., van Berkel T.J., and Kuiper J. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2642-2647
104. Veazey R.S., Klasse P.J., Schader S.M., Hu Q., Ketas T.J., Lu M., Marx P.A., Dufour J., Colonno R.J., Shattock R.J., Springer M.S., and Moore J.P. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438 (2005) 99-102
105. Wald O., Pappo O., Ari Z.B., Azzaria E., Wiess I.D., Gafnovitch I., Wald H., Spengler U., Galun E., and Peled A. The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection. Eur. J. Immunogenet 31 (2004) 249-252
106. Walker D.K., Abel S., Comby P., Muirhead G.J., Nedderman A.N., and Smith D.A. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. 33 (2005) 587-595
107. Watson C., Jenkinson S., Kazmierski W., and Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67 (2005) 1268-1282
108. Westby M., Lewis M., Whitcomb J., Youle M., Pozniak A.L., James I.T., Jenkins T.M., Perros M., and van der Ryst E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80 (2006) 4909-4920
109. M. Westby, C. Smith-Burchnell, D. Hamilton, N. Robas, B. Irvine, M. Fidock, J. Mills, F. Perruccio, J. Mori, M. Macartney, C. Barber, P. Dorr, M. Perros, UK-427,857-resistant Primary Isolates are Susceptible to Structurally-related CCR5 Antagonists, in: 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005
110. M. Westby, C. Smith-Burchnell, J. Mori, M. Lewis, J. Whitcomb, C. Petropoulos, M. Perros, In vitro escape of R5 primary isolates from the CCR5 antagonist, UK-427,857, is difficult to achieve and involves continued use of the CCR5 receptor, in: XIII International HIV Drug Resistance Workshop, Tenerife, 2004
111. Wise A., Gearing K., and Rees S. Target validation of G-protein coupled receptors. Drug. Discov. Today 7 (2002) 235-246
112. Wu L., Gerard N.P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A.A., Desjardin E., Newman W., Gerard C., and Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384 (1996) 179-183
113. Wu L., LaRosa G., Kassam N., Gordon C.J., Heath H., Ruffing N., Chen H., Humblias J., Samson M., Parmentier M., Moore J.P., and Mackay C.R. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186 (1997) 1373-1381
114. Zhu T., Mo H., Wang N., Nam D.S., Cao Y., Koup R.A., and Ho D.D. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261 (1993) 1179-1181